Espicom's in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year. Denmark is a global leader in the manufacture of insulin and as a consequence has retained a healthy balance of payments surplus for the past five years; in 2005, the surplus was in excess of US$606.4 million.
Prior to April 2005, there was a price freeze on pharmaceuticals and reimbursement levels were based upon reference prices in other northern European countries. Since then, reimbursement levels for each class have been based on the cheapest generic drug. This has led LiF, the Danish pharmaceutical trade association, to query how long the price freeze can be maintained, especially as there is a constant downward pressure on prices.
There is strong domestic production although many producers focus on Denmark's export market, therefore many pharmaceutical imports are in retail-ready packages. Parallel imported products constitute 12.1% of pharmaceuticals consumed in Denmark, with 34.9% of respiratory drugs being parallel imported.

The pharmaceutical market in Denmark is estimated to be valued at equal to US$686 per capita in 2007. Although 73.1% of the market originates in the primary care sector, pharmaceutical sales in the hospital sector averaged 14.7% growth per year in the period 2000-2005. In the primary care sector, pharmaceutical sales grew by 4.9% in a similar period.